© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
June 01, 2021
Secukinumab is the only fully human biologic that directly inhibits IL-17A.
April 26, 2021
While Janus Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.
Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.
April 25, 2021
A comparison of pooled phase 3 data showed patients treated with the IL-17A inhibitor fared better than those on ustekinumab, without influence from their PsA status.
The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.
April 24, 2021
New cross-sectional survey data suggest quality-of-life and psychological outcomes may differ in the most common chronic skin disease patient populations.
Patients who received ixekizumab achieved PASI 90 at a median of 43.0 days and PASI 100 at 85.0 days.
In a Q&A, Peter Lio, MD, discusses some evidence for using integrative therapies with patients.
April 23, 2021
Rebecca Kazin, MD, offers some insight into her cosmetic dermatology practices, including a new hair product that she developed.
A comparison of the IL-17 inhibitors suggest the more dynamic pathway-targeting biologic is more efficacious, but linked to more oral candidiasis.